A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques
Abstract
As the predominant aetiological agent of the common cold, human rhinovirus (HRV) is the leading cause of human infectious disease. Early studies showed that a monovalent formalin-inactivated HRV vaccine can be protective, and virus-neutralizing antibodies (nAb) correlated with protection. However, co-circulation of many HRV types discouraged further vaccine efforts. Here, we test the hypothesis that increasing virus input titres in polyvalent inactivated HRV vaccine may result in broad nAb responses. We show that serum nAb against many rhinovirus types can be induced by polyvalent, inactivated HRVs plus alhydrogel (alum) adjuvant. Using formulations up to 25-valent in mice and 50-valent in rhesus macaques, HRV vaccine immunogenicity was related to sufficient quantity of input antigens, and valency was not a major factor for potency or breadth of the response. Thus, we have generated a vaccine capable of inducing nAb responses to numerous and diverse HRV types.
Related
- Oral artificial microbio-vaccine triggers synergistic immunogenic cell death induction and tumor microenvironment remodeling for liver cancer therapy.
- Immunization Efficacy of a Commercialized Inactivated Mycoplasma bovis (Strain HM) Vaccine in Calves at a Large-Scale Dairy Farm in Yancheng, Jiangsu Province.
- A candidate gonococcal outer membrane vesicle vaccine which induces persistent immunity in three genetically distinct species of mouse and is similarly immunogenic when formulated with and without aluminium adjuvant
- Poly Pipeline: A Polyvalent Spatial Transcriptomics Workflow Validated Across Polyploid and Diploid Organisms
- Heat-Inactivated Lactiplantibacillus plantarum (RSB11) as a Multifunctional Postbiotic: Anti-Inflammatory Effects Compared with Live RSB11 Across Multiple Human Cell Models
BibTeX
@article{lee2026polyvalent,
title = {{A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques}},
author = {S. Lee and M. T. Nguyen and M. G. Currier and J. B. Jenkins and E. A. Strobert and A. E. Kajon and R. Madan-Lala and Y. A. Bochkov and J. E. Gern and K. Roy and X. Lu and D. D. Erdman and P. Spearman and M. L. Moore},
journal = {Nature Communications},
year = {2026},
month = oct,
doi = {10.1038/ncomms12838},
url = {https://hal.science/hal-05787882v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques
AU - S. Lee
AU - M. T. Nguyen
AU - M. G. Currier
AU - J. B. Jenkins
AU - E. A. Strobert
AU - A. E. Kajon
AU - R. Madan-Lala
AU - Y. A. Bochkov
AU - J. E. Gern
AU - K. Roy
AU - X. Lu
AU - D. D. Erdman
AU - P. Spearman
AU - M. L. Moore
PY - 2026
DA - 2026/10/09
JO - Nature Communications
DO - 10.1038/ncomms12838
UR - https://hal.science/hal-05787882v1
AB - As the predominant aetiological agent of the common cold, human rhinovirus (HRV) is the leading cause of human infectious disease. Early studies showed that a monovalent formalin-inactivated HRV vaccine can be protective, and virus-neutralizing antibodies (nAb) correlated with protection. However, co-circulation of many HRV types discouraged further vaccine efforts. Here, we test the hypothesis that increasing virus input titres in polyvalent inactivated HRV vaccine may result in broad nAb responses. We show that serum nAb against many rhinovirus types can be induced by polyvalent, inactivated HRVs plus alhydrogel (alum) adjuvant. Using formulations up to 25-valent in mice and 50-valent in rhesus macaques, HRV vaccine immunogenicity was related to sufficient quantity of input antigens, and valency was not a major factor for potency or breadth of the response. Thus, we have generated a vaccine capable of inducing nAb responses to numerous and diverse HRV types.
SN - 2041-1723
SN - 2041-1723
ER -